Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Center for Stem Cell and Organoid Medicine (CuSTOM), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States; Institute of Research, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Methods Cell Biol. 2020;159:47-68. doi: 10.1016/bs.mcb.2020.03.009. Epub 2020 May 22.
A growing number of in vitro hepatic models exist to study human genetics, liver biology, disease modeling and drug development and range from 2D hepatocytes to 3D multi-cellular tissues that are derived from human stem cells. However, stem cell-based models generally suffer from batch-, clone- and donor-dependent variability, hindering broader usage in diverse biomedical applications. To circumvent this challenge, we herein describe a reproducible protocol to generate human liver organoids in 20-25 days derived from pluripotent stem cells (PSCs). These organoids are intra-luminally polarized to form canalicular structures and are comprised of mainly hepatic epithelial cells, co-differentiated with stellate-like and hepatic macrophage-like cells that enables hepatic inflammatory disease modeling in vitro. These multi-lineage liver organoids express hepatocyte genes, secrete albumin and have vital metabolic functions. This protocol utilizes PSC derived 3D human liver organoids as a renewable, reproducible and personalized cell source, thus facilitating disease modeling and mechanistic studies with a future goal of developing novel therapeutics against currently intractable diseases.
越来越多的体外肝脏模型被用于研究人类遗传学、肝脏生物学、疾病建模和药物开发,范围从 2D 肝细胞到源自人类干细胞的 3D 多细胞组织。然而,基于干细胞的模型通常存在批次、克隆和供体依赖性变异性,这阻碍了它们在各种生物医学应用中的广泛使用。为了克服这一挑战,我们在此描述了一种在 20-25 天内从多能干细胞 (PSC) 生成人类肝类器官的可重复协议。这些类器官在腔内向极化形成胆小管结构,并主要由肝细胞组成,与星状细胞和肝巨噬细胞样细胞共分化,从而能够在体外进行肝炎症性疾病建模。这些多能性肝类器官表达肝细胞基因,分泌白蛋白,并具有重要的代谢功能。该方案利用 PSC 衍生的 3D 人类肝类器官作为可再生、可重复和个性化的细胞来源,从而促进疾病建模和机制研究,未来的目标是开发针对目前难以治疗疾病的新型治疗方法。